A Complete Research Report On Erectile Dysfunction Medication Introduction Erectile dysfunction (ED) is a typical sexual well being challenge affecting millions of men globally. It's characterized by the lack to realize or maintain an erection ample for passable sexual performance. In keeping with the Massachusetts Male Aging Research, the prevalence of ED will increase with age, affecting approximately 52% of males aged 40 to 70 years. Because the stigma surrounding sexual health diminishes and analysis progresses, numerous pharmacological interventions have emerged to deal with this condition. This report provides an outline of the first erectile dysfunction medicine, their mechanisms of action, efficacy, safety profiles, and future perspectives within the treatment of ED. Overview of Erectile Dysfunction Medications Erectile dysfunction medications are primarily categorized into a number of classes: Phosphodiesterase Type 5 Inhibitors (PDE5 Inhibitors) Hormonal Treatments Alprostadil Injection Therapies Novel Brokers in Development Phosphodiesterase Type 5 Inhibitors (PDE5 Inhibitors) PDE5 inhibitors are the most commonly prescribed medications for ED. They work by enhancing the effects of nitric oxide, a chemical that relaxes muscles within the penis and increases blood movement, facilitating an erection upon sexual stimulation. The primary PDE5 inhibitors embrace: 1. Sildenafil (Viagra) Sildenafil was the first oral medication approved for the treatment of ED in 1998. Clinical research have proven that it's efficient in roughly 60% to 80% of users. It sometimes lasts for about four to 5 hours and is taken roughly half-hour to one hour before sexual activity. 2.